Clinical Trial Phases Explained: From Phase 0 to Phase 4

Clinical trials are structured research studies that evaluate new medical interventions in humans through a sequence of phases, each designed to answer specific questions about safety, dosing, efficacy, and long-term effects. The phases progress from small exploratory studies in a handful of participants to large-scale confirmatory trials involving thousands of patients across multiple sites. Understanding what happens in each phase helps researchers, students, and professionals interpret trial results, assess the maturity of a therapeutic candidate, and make informed decisions about participation or collaboration. This article explains the purpose, design features, participant numbers, and endpoints associated with each phase from 0 through 4, and provides practical tools for identifying which phase a trial occupies based on observable characteristics.

The Purpose of Phased Clinical Development

The phased approach to clinical testing exists to protect participants while generating the evidence needed for regulatory approval and clinical adoption. Each phase builds on data from the previous one, with dose selection, safety monitoring, and efficacy assessments becoming progressively more rigorous. The drug development process involves four phases, with Phase III serving as the confirmatory step essential for regulatory approval of a specific treatment. Regulatory agencies place restrictions on confirmatory trials that use adaptive designs, meaning that modifications to trial procedures after enrollment begins are carefully constrained to preserve the integrity of the evidence.

The phases are not arbitrary divisions. They reflect a logical progression from first exposure in humans to post-marketing surveillance. A compound that fails to meet safety or efficacy thresholds in one phase typically does not advance to the next. This gatekeeping function is central to the entire enterprise. For example, an analysis of anti-obesity agents found that 92% of drugs fail during clinical trial testing for that indication, with combination therapies showing a transition probability roughly four times higher than monotherapies. The high failure rate underscores why phased testing exists: it identifies unpromising candidates before large populations are exposed.

Phase 0: Exploratory Microdosing Studies

Phase 0 trials are exploratory studies that involve very small doses of a drug, typically administered to a small number of participants, often fewer than 15. The objective is not therapeutic benefit but rather to gather preliminary pharmacokinetic and pharmacodynamic data, such as how the drug is absorbed, distributed, metabolized, and excreted, or whether it reaches its intended target tissue. These studies are sometimes called microdosing trials because the administered dose is far below the level expected to produce a pharmacological effect.

A Phase 0 trial can provide early evidence about whether a drug reaches its target organ at concentrations sufficient for activity. In one example, investigators used a Phase 0 design to assess whether gemcitabine penetrates tumors in diffuse intrinsic pontine glioma, a brain cancer with a history of failed chemotherapy trials. Patients received a single intravenous dose immediately before biopsy, and drug concentrations were measured in tumor tissue. The results showed intratumoral concentrations that compared favorably to levels associated with therapeutic effect in laboratory models, suggesting that poor drug penetration was not the reason for prior treatment failures. This type of information, obtained with minimal patient exposure, can redirect a development program before large efficacy trials are launched.

Phase 0 trials also carry practical challenges. Drug product stability is a critical concern because the investigational agent must remain within specifications throughout the study period. One Phase 0 program for a fluorescence-guided surgery agent was placed on hold when the Good Manufacturing Practices batch reached the end of its known stability period. New stability tests had to be developed and executed before the remaining patients could be treated, and regulatory permission was granted to complete the trial with stability testing performed for each patient. This example illustrates that Phase 0 trials, despite their small size, require the same attention to product quality and regulatory compliance as larger studies.

Phase 0 trials do not provide evidence of efficacy or safety sufficient to support marketing approval. They are best understood as a screening tool that helps sponsors decide whether a candidate merits further investment. The absence of therapeutic intent means that participants derive no direct medical benefit, which raises ethical considerations that must be addressed through careful informed consent and independent review.

Phase 1: Safety, Tolerability, and Dose Finding

Phase 1 trials are the first studies to administer a new intervention to humans. Their primary purpose is to evaluate safety and tolerability, typically in a small number of participants, often 20 to 80, generally spread across several dose levels. The focus is on identifying the range of doses that can be given safely, characterizing side effects, and understanding how the drug behaves in the body.

Dose escalation is a defining feature of Phase 1 trials. Early cohorts receive low doses, and subsequent cohorts receive higher doses only if the preceding dose level was tolerated. A common design is the 3+3 design, in which three participants are treated at a given dose level, and additional participants are enrolled if dose-limiting toxicity is observed. The goal is to identify the maximum tolerated dose, which becomes the recommended dose for later-phase studies. In a first-in-human trial of an oncolytic adenovirus delivered by neural stem cells for malignant glioma, investigators used a 3+3 design with three planned dose levels, starting at 6.25 x 10^10 viral particles and escalating to 1.875 x 10^11 viral particles. The primary endpoints were safety and tolerability, with survival outcomes and immune response as secondary endpoints.

Phase 1 trials are not limited to small molecules. They are used to evaluate vaccines, cell therapies, monoclonal antibodies, and medical devices. A Phase 1 trial of an aerosolized adenovirus type-5 vector-based COVID-19 vaccine randomly assigned participants to five groups receiving different routes and doses, including intramuscular injection, aerosol inhalation, or a combination of both. The primary safety outcome was adverse events within seven days after each vaccination, and the primary immunogenicity outcome was antibody and neutralizing antibody responses. This design allowed investigators to compare delivery methods early in development.

Phase 1 trials can also generate preliminary signals of biological activity. A Phase 1 trial of human umbilical cord-derived mesenchymal stem cells in patients with moderate and severe COVID-19 enrolled 18 hospitalized patients, with nine receiving three intravenous infusions of stem cells and nine receiving standard treatment alone. No serious infusion-associated adverse events were observed, and the authors concluded that the treatment was safe and well tolerated, while noting that randomized controlled trials with long-term follow-up were needed to evaluate therapeutic efficacy.

Phase 1 trials carry the highest risk of unknown adverse effects because the intervention has limited prior human exposure. This risk is managed through intensive monitoring, predefined stopping rules, and careful selection of participants, who often have conditions for which standard treatments have failed. The safety data generated in Phase 1 inform the design of Phase 2 trials, including dose selection, dosing schedule, and the specific adverse events that warrant close monitoring.

Phase 2: Efficacy Signal and Further Safety Assessment

Phase 2 trials are designed to determine whether a new treatment has sufficiently promising efficacy to warrant further investigation in a large-scale randomized Phase 3 trial, as well as to further assess safety. These studies usually involve a few hundred patients. The emphasis shifts from dose finding to preliminary evidence of clinical benefit, although the primary endpoints are often surrogate measures or intermediate outcomes instead of definitive clinical outcomes.

Several Phase 2 designs are commonly used, each with distinct strengths and limitations. Single-arm designs treat all participants with the investigational drug and compare outcomes to historical controls. Randomized designs assign participants to treatment or control groups, which may include placebo, standard of care, or an active comparator. The choice of design depends on the disease, the availability of effective treatments, and the strength of prior evidence. A comparison of three potential designs in the context of the NRG-HN002 trial, a study in head and neck cancer, illustrates how different designs can yield different conclusions about whether a treatment warrants Phase 3 testing.

Phase 2 trials often use biomarkers or intermediate endpoints to make go or no-go decisions. For example, a trial might measure tumor response rate, change in a laboratory parameter, or improvement in a functional assessment. These endpoints are selected because they are expected to predict longer-term clinical benefit, but the relationship is not always certain. A treatment that improves a surrogate endpoint may not improve survival or quality of life, and a treatment that fails to improve a surrogate endpoint may still provide clinical benefit through other mechanisms.

The run-in phase is a design element sometimes used in Phase 2 and Phase 3 trials. A run-in period occurs before randomization and is used to exclude non-adherent patients, placebo responders, active drug non-responders, or patients who do not tolerate the active drug. An analysis of trials for four dipeptidyl peptidase-4 inhibitors found that 88 of 106 qualifying trials included run-in phases, with an average duration of 4.0 weeks and a range of 1 to 21 weeks. The analysis found that trials with run-in phases provided similar estimates for medication efficacy and safety compared to trials without run-in phases, suggesting that the run-in design does not systematically distort results, although it may affect generalizability.

Phase 2 trials are also where combination therapies are often first evaluated. An analysis of anti-obesity agents found that combination therapies had a transition probability of 40% compared to 4.75% for monotherapies, a roughly ten-fold difference. This finding suggests that combination approaches may be more likely to succeed in later-phase testing, although the reasons for this difference require further investigation.

Phase 3: Confirmatory Efficacy and Safety

Phase 3 trials are large, randomized, controlled studies designed to confirm the efficacy and safety of a treatment in a patient population that reflects the intended use population. These trials are the confirmatory step essential for regulatory approval of a specific treatment. They typically enroll hundreds to thousands of participants across multiple sites and may continue for several years.

The design of Phase 3 trials is governed by regulatory requirements that prioritize internal validity. Randomization, blinding, and pre-specified endpoints are standard features. The primary endpoint is usually a clinically meaningful outcome, such as survival, disease progression, or a validated symptom measure. Secondary endpoints may include quality of life, additional efficacy measures, and safety outcomes.

The PREEMPT clinical program for onabotulinumtoxinA in chronic migraine provides an example of Phase 3 trial design and execution. The program included two multicenter, pivotal trials, each with a 24-week randomized, double-blind phase followed by a 32-week open-label phase. Patients were randomized to receive onabotulinumtoxinA or placebo injections every 12 weeks, with study visits every 4 weeks. The trials were identical in design except for the designation of primary and secondary endpoints, which allowed the results to be pooled for analysis. The primary endpoint for the pooled analysis was the mean change from baseline in the frequency of headache days at 24 weeks, with secondary endpoints including migraine days, moderate or severe headache days, total cumulative hours of headache, headache episodes, and acute headache pain medication intakes.

Phase 3 trials are expensive and time-consuming, and their results determine whether a treatment receives regulatory approval. The transition probability from Phase 3 to approval varies by therapeutic area. For anti-obesity agents, the overall transition probability from Phase 1 through approval was 8.50%, compared to an industry standard of 10.40%. These figures illustrate the high attrition rate that persists even in late-stage development.

Regulatory agencies impose restrictions on adaptive designs in confirmatory trials. Adaptive designs allow pre-specified modifications to trial procedures based on interim data, such as sample size reassessment or treatment arm dropping. While these designs can improve efficiency, they also introduce statistical complexities and the potential for bias. Regulatory guidance requires that adaptations be pre-specified, that the statistical analysis plan account for them, and that the integrity of the trial be preserved.

Phase 4: Post-Marketing Surveillance and Long-Term Safety

Phase 4 trials are conducted after a treatment has received regulatory approval and is available to the general population. These studies are also known as post-marketing surveillance studies. Their purpose is to monitor long-term safety, detect rare adverse events, evaluate effectiveness in real-world populations, and identify potential new indications.

Phase 4 trials differ from earlier phases in several important ways. Participants are not selected according to the narrow eligibility criteria used in registration trials. Instead, they reflect the diversity of the general population, including patients with comorbidities, concurrent medications, and demographic characteristics that may have been underrepresented in earlier trials. This broader population can reveal adverse effects that were too rare or too delayed to be detected in Phase 3 trials.

Phase 4 studies may be required by regulatory authorities as a condition of approval. These commitments may include registries, observational studies, or additional randomized trials. The specific requirements depend on the treatment, the disease, and the uncertainties identified during the review process.

Phase 4 trials also contribute to the evidence base for clinical decision-making. Comparative effectiveness research, which compares approved treatments against each other, is often conducted in the post-marketing period. These studies help clinicians and patients choose among available options based on real-world outcomes.

At a Glance: Phase Comparison Table

The following table summarizes the key characteristics of each clinical trial phase. Use it to quickly identify which phase a trial occupies based on its objectives, participant numbers, and endpoints.

Decision Table: Identifying the Phase of a Clinical Trial

The following decision table helps readers identify which phase a trial is in based on observable characteristics. Start at the top and follow the criteria that match the trial description.

Practical Steps for Assessing a Trial's Phase

When you encounter a clinical trial, whether in a publication, a registry, or a news report, you can determine its phase by following a systematic assessment. These steps apply to students, researchers, and professionals who need to interpret trial results accurately.

First, locate the trial registration record. Most interventional trials are registered in a public registry such as ClinicalTrials.gov, and the registration includes the phase designation. The registration also contains the primary outcome measures, enrollment target, and study design, which provide additional context.

Second, examine the primary outcome measure. If the primary outcome is a safety measure such as dose-limiting toxicity or adverse event frequency, the trial is likely Phase 1. If the primary outcome is a preliminary efficacy measure such as response rate or a biomarker change, the trial is likely Phase 2. If the primary outcome is a definitive clinical outcome such as survival or disease progression, the trial is likely Phase 3.

Third, assess the number of participants and the number of sites. Phase 1 trials typically enroll fewer than 100 participants at one or a few sites. Phase 2 trials enroll a few hundred participants, often at multiple sites. Phase 3 trials enroll hundreds to thousands of participants at many sites. Phase 4 trials may enroll thousands of participants or use existing data sources.

Fourth, consider the control group. Phase 1 trials often have no control group, although some include placebo controls in dose-escalation designs. Phase 2 trials may be single-arm or randomized. Phase 3 trials are almost always randomized and often blinded. Phase 4 trials may be observational or interventional.

Fifth, review the stated purpose in the trial description. Sponsors and investigators usually state whether the trial is designed to assess safety, efficacy, or both. This statement, combined with the other characteristics, provides a reliable basis for phase identification.

Records and Measurements in Clinical Trials

Accurate record keeping is fundamental to the validity of clinical trial results. Each phase generates specific types of data that must be collected, verified, and analyzed according to pre-specified protocols.

Safety records include adverse event logs, laboratory values, vital signs, and physical examination findings. In Phase 1 trials, these records are collected frequently, often at every visit and sometimes between visits. Dose-limiting toxicity is defined in the protocol and triggers specific actions, such as stopping enrollment at a dose level or expanding a cohort to confirm a safety signal.

Pharmacokinetic records document drug concentrations in blood, plasma, or other biological matrices over time. These data are used to calculate parameters such as maximum concentration, time to maximum concentration, half-life, and area under the curve. Bioanalytical method validation is a prerequisite for reliable pharmacokinetic data. Regulatory guidance specifies the requirements for demonstrating that an analytical method is accurate, precise, selective, and reproducible for its intended use.

Efficacy records depend on the disease and the endpoint. Tumor response may be assessed by imaging, symptom scores by patient-reported questionnaires, and biomarker changes by laboratory assays. The protocol must specify how each endpoint is measured, when it is measured, and how missing data are handled.

Quality records document the conduct of the trial, including protocol deviations, amendments, and monitoring visits. These records support the integrity of the trial and are reviewed by regulatory authorities during inspections.

Common Failure Patterns in Clinical Trial Phases

Understanding why trials fail helps researchers design better studies and helps readers interpret negative results. Several failure patterns recur across therapeutic areas.

Phase 1 failures are most often due to safety concerns. A drug may cause unexpected toxicity at doses below the predicted therapeutic range, or the maximum tolerated dose may be lower than the dose needed for efficacy. Phase 1 trials may also fail because the drug does not achieve adequate exposure in the target tissue, a finding that can be detected in Phase 0 or Phase 1 pharmacokinetic studies.

Phase 2 failures are often due to insufficient efficacy. A treatment may show a signal in a small single-arm study but fail to separate from placebo or standard of care in a randomized comparison. The choice of endpoint is critical. A surrogate endpoint that does not predict clinical benefit can lead to a false positive or false negative decision.

Phase 3 failures are the most costly. A treatment that appeared promising in Phase 2 may fail to confirm efficacy in a larger, more diverse population. The effect size may be smaller than expected, the control group may perform better than anticipated, or the treatment may be associated with rare but serious adverse events that were not detected earlier.

Phase 4 failures involve the identification of new safety signals after approval. These may lead to label changes, restricted use, or withdrawal from the market. The detection of rare adverse events requires large exposed populations and robust pharmacovigilance systems.

Safety and Regulatory Context

Participant safety is the overriding concern at every phase of clinical development. The ethical and regulatory framework for clinical trials is designed to ensure that the risks of participation are justified by the potential benefits, that participants provide informed consent, and that independent oversight is maintained.

Clinical trial documents are complex and may contain inconsistencies that lead to implementation errors and compromise participant safety. A study of oncology trial documents found that 269 of 585 trials reviewed required interventions, with 171 of 1001 interventions classified as potential patient safety interventions. Most safety interventions were medication related, with drug dosing interventions most frequently identified. Phase 1 trials had the highest proportion of safety interventions per trial compared with all other phases, and investigator-initiated trials had the highest proportion of safety interventions of all sponsor types. These findings highlight the importance of careful document review and centralized oversight.

Laboratory quality is a component of trial safety. The World Health Organization Laboratory Quality Management System Handbook provides guidance for establishing and maintaining quality in laboratories that generate trial data. The Laboratory Biosafety Manual addresses the safe handling of biological materials, which is relevant to trials involving infectious agents or biological samples.

Regulatory requirements vary by jurisdiction. The U.S. Food and Drug Administration publishes guidance documents on topics such as bioanalytical method validation, which specifies the expectations for analytical methods used in pharmacokinetic and toxicokinetic studies. The National Center for Advancing Translational Sciences maintains the Assay Guidance Manual, which provides recommendations for developing and validating assays used in drug discovery and development.

Limitations and Professional Escalation Criteria

Clinical trial phases have limitations that readers should understand. The phase designation does not guarantee a specific design, and some trials combine elements of multiple phases. For example, a Phase 1/2 trial may evaluate safety and preliminary efficacy in a single protocol, with a dose-escalation stage followed by an expansion cohort. Similarly, a Phase 2/3 trial may use an adaptive design that begins as a Phase 2 study and expands to a Phase 3 study based on interim results.

The participant numbers associated with each phase are typical ranges, not fixed requirements. A Phase 1 trial may enroll more than 80 participants if the dose-escalation design requires multiple cohorts, and a Phase 2 trial may enroll fewer than 100 participants if the effect size is expected to be large.

The endpoints associated with each phase are also flexible. Some Phase 2 trials use clinical outcomes instead of surrogates, and some Phase 3 trials include biomarker endpoints as secondary measures. The phase designation reflects the stage of development and the primary question being asked, not the specific statistical methods or endpoint choices.

Professional escalation criteria apply when trial results are used to make decisions about patient care, regulatory submissions, or further investment. If a trial result conflicts with established evidence, if the trial design has significant limitations, or if the results are being used beyond the population studied, consultation with a qualified professional is appropriate. Similarly, if a safety signal is identified in a post-marketing setting, it should be reported through the appropriate pharmacovigilance channels.

Frequently Asked Questions

What is the difference between Phase 0 and Phase 1 trials?

Phase 0 trials involve microdoses of a drug in a small number of participants, often fewer than 15, and are designed to gather preliminary pharmacokinetic data or assess whether the drug reaches its target tissue. They have no therapeutic intent. Phase 1 trials involve larger doses and enroll 20 to 80 participants, with the primary goal of evaluating safety, tolerability, and the maximum tolerated dose. Phase 0 trials are optional and are used to screen candidates before committing to a full Phase 1 program.

How many participants are typically enrolled in a Phase 2 trial?

Phase 2 trials usually involve a few hundred patients. The exact number depends on the disease, the expected effect size, and the study design. Single-arm trials may enroll fewer participants than randomized trials, and trials with large expected effects may require smaller sample sizes than trials with modest expected effects.

What is the primary endpoint in a Phase 3 trial?

The primary endpoint in a Phase 3 trial is usually a clinically meaningful outcome such as survival, disease progression, or a validated symptom measure. The choice of endpoint depends on the disease and the treatment. Regulatory agencies require that the primary endpoint be clinically relevant and that the trial be designed to detect a pre-specified difference between treatment groups.

Are Phase 4 trials always required after drug approval?

Phase 4 trials are not always required, but they may be mandated by regulatory authorities as a condition of approval when there are uncertainties about long-term safety or effectiveness. Many approved drugs are studied in Phase 4 trials voluntarily to generate additional evidence for clinical decision-making and to detect rare adverse events.

What is a run-in phase in a clinical trial?

A run-in phase is a period before randomization in which participants receive a placebo or the active drug to assess adherence, tolerance, or response. Participants who do not adhere to the regimen, who experience intolerable side effects, or who respond to placebo may be excluded before randomization. Run-in phases can improve the efficiency of a trial but may affect the generalizability of the results.

How do adaptive designs affect the interpretation of Phase 3 trials?

Adaptive designs allow pre-specified modifications to trial procedures based on interim data, such as sample size reassessment or treatment arm dropping. Regulatory agencies impose restrictions on adaptive designs in confirmatory trials to preserve the integrity of the evidence. The statistical analysis plan must account for the adaptations, and the results must be interpreted in light of the design.

What are the most common reasons for drug failure in clinical trials?

Drug failure can occur at any phase. Phase 1 failures are often due to safety concerns. Phase 2 failures are often due to insufficient efficacy. Phase 3 failures may result from a smaller than expected effect size, a better than expected control group performance, or rare adverse events. An analysis of anti-obesity agents found that 92% of drugs fail during clinical trial testing for that indication.

How can I identify which phase a clinical trial is in?

You can identify the phase by reviewing the trial registration record, which includes the phase designation, primary outcome measures, enrollment target, and study design. Additional clues include the number of participants, the presence of a control group, the type of endpoint, and the stated purpose of the trial. The decision table in this article provides a structured approach to phase identification.

Related Articles

• Cytotoxicity Assay: Overview of LDH, MTT, and ATP-Based Methods
• Spread Plate vs Pour Plate vs Streak Plate: Which Method to Use
• Development of an Aptamer-Based Electrochemical Biosensor for Rapid Detection of Canine Parvovirus in Clinical Samples
• CRISPR-Cas12a-Based Nucleic Acid Detection for Rapid Diagnosis of Canine Distemper Virus in Clinical Samples
• Digital Droplet PCR (ddPCR) for Absolute Quantification of Swine Enteric Coronaviruses in Fecal and Oral Fluid Samples: Analytical Sensitivity and Clinical Utility

References and Further Reading

• Laboratory Quality Management System Handbook. World Health Organization.
• Laboratory Biosafety Manual. World Health Organization.
• Assay Guidance Manual. National Center for Advancing Translational Sciences.
• Bioanalytical Method Validation Guidance. U.S. Food and Drug Administration.
• NCBI Literature Resources. National Center for Biotechnology Information.
• PubMed. National Library of Medicine.
• An Overview of Phase 2 Clinical Trial Designs.. International journal of radiation oncology, biology, physics, 2022.
• OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.. Headache, 2010.
• Impact of Menstrual cycle-based Periodized training on Aerobic performance, a Clinical Trial study protocol-the IMPACT study.. Trials, 2024.
• Palonosetron.. Drugs, 2004.
• Clinical trial success rates of anti-obesity agents: the importance of combination therapies.. Obesity reviews : an official journal of the International Association for the Study of Obesity, 2015.
• Reinventing clinical trials: a review of innovative biomarker trial designs in cancer therapies.. British medical bulletin, 2015.
• Preventing Potential Patient Harm Through Clinical Content Interventions During Oncology Clinical Trial Implementation.. Journal of patient safety, 2023.
• Application and impact of run-in studies.. Journal of general internal medicine, 2018.
• Perspectives on the Phase 0 clinical trial of microdose administration of ABY-029 for fluorescence guided surgery: Stability testing.. 2020.
• DIPG-77. INTRATUMORAL PHARMACOKINETICS OF CHEMOTHERAPY IN DIPG: XENOGRAFT AND INITIAL PHASE 0 CLINICAL TRIAL RESULTS. 2018.
• OS1.6 Characterizing the Over-expression of Yki/YAP/TAZ Transcription Factors in Gliomagenesis and Results of a Phase 0 Clinical Trial for a Proposed Novel Treatment of Glioblastomas. 2018.
• Rapamycin treatment for Alzheimer’s disease and related dementias: a pilot phase 1 clinical trial. Communications Medicine, 2025.
• Radiation enhancement using focussed ultrasound-stimulated microbubbles for breast cancer: A Phase 1 clinical trial. PLoS Medicine, 2024.
• Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduction and Targeted Therapy, 2020.
• Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet. Infectious Diseases (Print), 2021.
• Neural Stem Cell Delivery of an Oncolytic Adenovirus in Newly DiagnosedMalignant Glioma: A First-in-Human, Phase 1 Clinical Trial. The Lancet Oncology, 2021.
• Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nature Medicine, 2022.
• Phase 2 Clinical Trials. Introduction to Basics of Pharmacology and Toxicology Volume 4 Pharmacology and Therapeutics, 2025.

This article is educational and does not replace institutional policy, professional advice, or applicable safety and regulatory requirements.